Evidence map›Paper›PMID 29089968›Full record

ArticleJournal of geriatric cardiology : JGC2017

Targeting of AUF1 to vascular endothelial cells as a novel anti-aging therapy.

Jian He, Ya-Feng Jiang, Liu Liang, Du-Jin Wang, Wen-Xin Wei, Pan-Pan Ji, Yao-Chan Huang, Hui Song, Xiao-Ling Lu, Yong-Xiang Zhao

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of geriatric cardiology : JGC, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Sulfur dioxide improves endothelial dysfunction by downregulating the angiotensin II/ATJournal of the renin-angiotensin-aldosterone system : JRAAS
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jian HeNational Center for International Research of Biological Targeting Diagnosis and Therapy; Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research; Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China.
Ya-Feng JiangNational Center for International Research of Biological Targeting Diagnosis and Therapy; Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research; Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China.
Liu LiangNational Center for International Research of Biological Targeting Diagnosis and Therapy; Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research; Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China.
Du-Jin WangNational Center for International Research of Biological Targeting Diagnosis and Therapy; Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research; Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China.
Wen-Xin WeiNational Center for International Research of Biological Targeting Diagnosis and Therapy; Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research; Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China.
Pan-Pan JiNational Center for International Research of Biological Targeting Diagnosis and Therapy; Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research; Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China.
Yao-Chan HuangNational Center for International Research of Biological Targeting Diagnosis and Therapy; Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research; Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China.
Hui SongNational Center for International Research of Biological Targeting Diagnosis and Therapy; Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research; Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China.
Xiao-Ling LuNational Center for International Research of Biological Targeting Diagnosis and Therapy; Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research; Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China.
Yong-Xiang ZhaoNational Center for International Research of Biological Targeting Diagnosis and Therapy; Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research; Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China.
Target (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInhibition of aging of vascular endothelial cells (VECs) may delay aging and prolong life. The goal of this study was to prepare anti-CD31 monoclonal antibody conjugated PEG-modified liposomes containing the AU-rich region connecting factor 1 (AUF1) gene (CD31-PILs-AUF1) and to explore the effects of targeting CD31-PILs-AUF1 to aging VECs.

methodsThe mean particle sizes of various PEGylated immunoliposomes (PILs) were measured using a Zetasizer Nano ZS. Gel retardation assay was used to confirm whether PILs had encapsulated the AUF1 plasmid successfully. Fluorescence microscopy and flow cytometry were used to quantify binding of CD31-PILs-AUF1 to target cells. Flow cytometry was also used to analyze the cell cycles of aging bEnd3 cells treated with CD31-PILs-AUF1. We also developed an aging mouse model by treating mice with D-galactose. Enzyme-linked immunosorbent assay (ELISA) was used to evaluate the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). The malondialdehyde (MDA) and the superoxide dismutase (SOD) levels were detected by commercial kits. Hematoxylin-eosin (HE) staining was used to determine whether treatment with CD31-PILs-AUF1 was toxic to the mice.

resultsCD31-PILs-AUF1 specifically could targeted bEnd3 VECs and increased the percentage of cells in the S and G2/M phases of aging bEnd3 cells. ELISA showed that content of the IL-6 and TNF-α decreased in CD31-PILs-AUF1 group. The level of SOD increased, whereas MDA decreased in the CD31-PILs-AUF1 group. Additionally, CD31-PILs-AUF1 was not toxic to the mice.

conclusionCD31-PILs-AUF1 targets VECs and may delay their senescence.

Indexed as

AgingAU-rich region connecting factor 1PEGylated immunoliposomesVascular endothelial cells

Identifiers

PMID29089968
PMCPMC5653898
OpenAlexW2758224243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.